Pôle FATH
- Corbet C, Bastien E, Draoui N, Doix B, Mignion L, Jordan BF, Marchand A, Vanherck JC, Chaltin P, Schakman O, Becker HM, Riant O and Feron O. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels tumor growth inhibitory and radiosensitizing effects. Nature Comm 2018.
- Corbet C, Feron O. Tumour acidosis: from the passenger to the driver's seat. Nature Rev Cancer. 2017 Oct;17(10):577-593.
- Brisson L, Bański P, Sboarina M, Dethier C, Danhier P, Fontenille MJ, Van Hée VF, Vazeille T, Tardy M, Falces J, Bouzin C, Porporato PE, Frédérick R, Michiels C, Copetti T, Sonveaux P. Lactate Dehydrogenase B Controls Lysosome Activity and Autophagy in Cancer. Cancer Cell. 2016 Sep 12;30(3):418-431.
- Corbet C, Pinto A, Martherus R, Santiago de Jesus JP, Polet F, Feron O. Acidosis Drives the Reprogramming of Fatty Acid Metabolism in Cancer Cells through Changes in Mitochondrial and Histone Acetylation. Cell Metab. 2016 Aug 9;24(2):311-23.
Pôle MIRO
- B. Mlecnik*, M. Van den Eynde*, G. Bindea*, S. Church, A. Vasaturo, T. Fredriksen, L. Lafontaine, N. Haicheur, F. Marliot, D. Debetancourt, G. Pairet, A. Jouret-Mourin, JF. Gigot, C. Hubert, E. Danse, C. Dragean, J. Carrasco, Y. Humblet, V. Valge-Archer, A. Berger, F. Pagès, JP Machiels, J. Galon. Comprehensive immune quantification shows metastasis heterogeneity and major impact of Immunoscore on survival. J Natl Cancer Inst 2018 Jan 1;110(1).
- F. Pagès, B. Mlecnik, F. Marliot, G. Bindea, F. Ou, C Bifulco, A. Lugli, I. Zlobec, T. Rau, M. Berger, D. Nagtegaal, E. Vink-Börger, A. Hartmann, C. Geppert, J. Kolwelter, S. Merkel, R. Grützmann, M. Van den Eynde, et al. International validation of the consensus Immunoscore for the prognostic classification of colon cancer. Lancet 2018, in press.
- Cohen EE, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, del Campo JM, Mailliez A, Hadda RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Kräer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, and Machiels JP. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Annal Oncol 2017; 28:2526-2532
- Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD. JAMA Oncol. 2017 Nov 1;3(11):1511-1519.